Impact of combined use of intraoperative MRI and awake microsurgical resection on patients with gliomas: a systematic review and meta-analysis.


Journal

Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 05 10 2020
accepted: 25 01 2021
revised: 29 12 2020
pubmed: 5 2 2021
medline: 18 11 2021
entrez: 4 2 2021
Statut: ppublish

Résumé

Microsurgical resection of primary brain tumors located within or near eloquent areas is challenging. Primary aim is to preserve neurological function, while maximizing the extent of resection (EOR), to optimize long-term neurooncological outcomes and quality of life. Here, we review the combined integration of awake craniotomy and intraoperative MRI (IoMRI) for primary brain tumors, due to their multiple challenges. A systematic review of the literature was performed, in accordance with the Prisma guidelines. Were included 13 series and a total number of 527 patients, who underwent 541 surgeries. We paid particular attention to operative time, rate of intraoperative seizures, rate of initial complete resection at the time of first IoMRI, the final complete gross total resection (GTR, complete radiological resection rates), and the immediate and definitive postoperative neurological complications. The mean duration of surgery was 6.3 h (median 7.05, range 3.8-7.9). The intraoperative seizure rate was 3.7% (range 1.4-6; I^2 = 0%, P heterogeneity = 0.569, standard error = 0.012, p = 0.002). The intraoperative complete resection rate at the time of first IoMRI was 35.2% (range 25.7-44.7; I^2 = 66.73%, P heterogeneity = 0.004, standard error = 0.048, p < 0.001). The rate of patients who underwent supplementary resection after one or several IoMRI was 46% (range 39.8-52.2; I^2 = 8.49%, P heterogeneity = 0.364, standard error = 0.032, p < 0.001). The GTR rate at discharge was 56.3% (range 47.5-65.1; I^2 = 60.19%, P heterogeneity = 0.01, standard error = 0.045, p < 0.001). The rate of immediate postoperative complications was 27.4% (range 15.2-39.6; I^2 = 92.62%, P heterogeneity < 0.001, standard error = 0.062, p < 0.001). The rate of permanent postoperative complications was 4.1% (range 1.3-6.9; I^2 = 38.52%, P heterogeneity = 0.123, standard error = 0.014, p = 0.004). Combined use of awake craniotomy and IoMRI can help in maximizing brain tumor resection in selected patients. The technical obstacles to doing so are not severe and can be managed by experienced neurosurgery and anesthesiology teams. The benefits of bringing these technologies to bear on patients with brain tumors in or near language areas are obvious. The lack of equipoise on this topic by experienced practitioners will make it difficult to do a prospective, randomized, clinical trial. In the opinion of the authors, such a trial would be unnecessary and would deprive some patients of the benefits of the best available methods for their tumor resections.

Identifiants

pubmed: 33537890
doi: 10.1007/s10143-021-01488-3
pii: 10.1007/s10143-021-01488-3
pmc: PMC8592967
doi:

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2977-2990

Subventions

Organisme : Université de Lausanne
ID : Jeune Chercheur en Recherche Clinique

Informations de copyright

© 2021. The Author(s).

Références

J Neurosurg. 2014 Oct;121(4):810-7
pubmed: 25105702
Neurosurg Focus. 2016 Mar;40(3):E14
pubmed: 26926054
Cancer Control. 2003 Mar-Apr;10(2):115-24
pubmed: 12712006
Acta Neurochir (Wien). 1999;141(11):1157-67
pubmed: 10592115
J Clin Neurosci. 2013 Sep;20(9):1280-7
pubmed: 23850046
J Neurosurg. 2019 Jan 25;:1-9
pubmed: 30684941
Neurosurgery. 2010 Jan;66(1):113-20
pubmed: 19935438
Neurosurgery. 2011 Jul;69(1):194-205; discussion 205-6
pubmed: 21499143
Acta Neurochir (Wien). 2010 Nov;152(11):1835-46
pubmed: 20730457
J Neurooncol. 1997 Aug;34(1):85-101
pubmed: 9210055
Minim Invasive Neurosurg. 2005 Apr;48(2):77-84
pubmed: 15906201
J Neurosurg. 2003 Sep;99(3):467-73
pubmed: 12959431
Acta Neurochir (Wien). 2007 Dec;149(12):1197-8
pubmed: 18075724
World Neurosurg. 2010 May;73(5):547-51
pubmed: 20920940
J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):845-51
pubmed: 15897509
Top Magn Reson Imaging. 2009 Jan;19(4):191-6
pubmed: 19148035
J Neurosurg. 2015 Sep;123(3):711-20
pubmed: 26047412
Expert Rev Neurother. 2005 Jul;5(4):473-85
pubmed: 16026231
Neurosurgery. 2016 Jun;78(6):775-86
pubmed: 26516822
Acta Neurochir (Wien). 2019 Jul;161(7):1467-1474
pubmed: 31073784
Acta Neurochir Suppl. 2011;109:43-8
pubmed: 20960319
Neuroimage. 2007;37 Suppl 1:S100-8
pubmed: 17572109
J Neurol Surg A Cent Eur Neurosurg. 2021 Jul;82(4):375-380
pubmed: 31659724
Med Phys. 2000 Apr;27(4):787-800
pubmed: 10798702
Minerva Anestesiol. 2008 Jul-Aug;74(7-8):393-408
pubmed: 18612268
Neurosurgery. 2009 Jun;64(6):1073-81; discussion 1081
pubmed: 19487886
Neuroimage Clin. 2012 Dec 12;2:132-42
pubmed: 24179766
Neurosurg Clin N Am. 2005 Jan;16(1):135-41
pubmed: 15561533
J Neurosurg. 2018 May;128(5):1410-1418
pubmed: 28731401
Stereotact Funct Neurosurg. 2018;96(3):172-181
pubmed: 30041248
J Neurosurg. 2009 Dec;111(6):1185-90
pubmed: 19499978
Neurosurgery. 1989 Nov;25(5):786-92
pubmed: 2586730
Neurochirurgie. 2017 Jun;63(3):181-188
pubmed: 28571707
World Neurosurg. 2016 May;89:84-92
pubmed: 26851745
Surg Neurol Int. 2012;3(Suppl 4):S320-7
pubmed: 23230537
Neurosurgery. 2016 Jan;78(1):53-61
pubmed: 26313220
Neurosurgery. 1998 Jun;42(6):1312-6; discussion 1316-7
pubmed: 9632190
Acta Neurochir (Wien). 2013 Oct;155(10):1805-12
pubmed: 23955509
Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6
pubmed: 18496181
Neurosurg Focus. 1998 Apr 15;4(4):e8
pubmed: 17168508
Eur J Anaesthesiol. 2008 Aug;25(8):662-9
pubmed: 18289443
J Neurosurg. 2011 Mar;114(3):719-26
pubmed: 20964594
J Clin Oncol. 2012 Jul 10;30(20):2559-65
pubmed: 22529254
Acta Neurochir Suppl. 2017;124:309-313
pubmed: 28120089
Front Oncol. 2018 Oct 10;8:434
pubmed: 30364103
Lancet Oncol. 2011 Oct;12(11):997-1003
pubmed: 21868284
J Neurosurg. 2000 Dec;93(6):1003-13
pubmed: 11117842
Acta Neurochir Suppl. 2011;109:61-5
pubmed: 20960322
Surg Neurol. 1997 Apr;47(4):380-8
pubmed: 9122843
N Engl J Med. 2008 Jan 3;358(1):18-27
pubmed: 18172171
J Neurosurg. 2014 May;120(5):1015-24
pubmed: 24628613
J Neurosurg. 2017 Oct;127(4):790-797
pubmed: 28059650
J Neurosurg. 1989 Sep;71(3):316-26
pubmed: 2769383
Phys Ther. 2009 Sep;89(9):873-80
pubmed: 19723669
J Neurosurg. 1998 Feb;88(2):349-51
pubmed: 9452250
Nature. 1977 Nov 3;270(5632):50-1
pubmed: 927514
Neurol Res. 2006 Jul;28(5):482-7
pubmed: 16808876
Neurosurgery. 2004 Jan;54(1):113-7; discussion 118
pubmed: 14683547
Cancer. 1994 Sep 15;74(6):1784-91
pubmed: 8082081
Neurosurgery. 2000 Mar;46(3):632-41; discussion 641-2
pubmed: 10719860

Auteurs

Constantin Tuleasca (C)

Neurosurgery and Neurooncology Service, Centre Hospitalier Regional Universitaire de Lille, Roger Salengro Hospital, Lille, France. constantin.tuleasca@chuv.ch.
Department of Clinical Neurosciences, Neurosurgery Service and Gamma Knife Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland. constantin.tuleasca@chuv.ch.
Faculty of Biology and Medicine (FBM), University of Lausanne (Unil), Lausanne, Switzerland. constantin.tuleasca@chuv.ch.
Signal Processing Laboratory (LTS 5), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. constantin.tuleasca@chuv.ch.

Henri-Arthur Leroy (HA)

Neurosurgery and Neurooncology Service, Centre Hospitalier Regional Universitaire de Lille, Roger Salengro Hospital, Lille, France.

Iulia Peciu-Florianu (I)

Neurosurgery and Neurooncology Service, Centre Hospitalier Regional Universitaire de Lille, Roger Salengro Hospital, Lille, France.

Ondine Strachowski (O)

Neurosurgery and Neurooncology Service, Centre Hospitalier Regional Universitaire de Lille, Roger Salengro Hospital, Lille, France.

Benoit Derre (B)

Neurosurgery and Neurooncology Service, Centre Hospitalier Regional Universitaire de Lille, Roger Salengro Hospital, Lille, France.

Marc Levivier (M)

Department of Clinical Neurosciences, Neurosurgery Service and Gamma Knife Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Faculty of Biology and Medicine (FBM), University of Lausanne (Unil), Lausanne, Switzerland.

Michael Schulder (M)

Department of Neurosurgery, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA.

Nicolas Reyns (N)

Neurosurgery and Neurooncology Service, Centre Hospitalier Regional Universitaire de Lille, Roger Salengro Hospital, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH